Preclinical IBD Program — IND submission
Dec 2026
We continue to advance our Preclinical IBD Program, with the goal of having a product candidate ready for an Investigational New Drug ("IND Application") with the FDA by December 2026.Source filing
VIVS biotech catalysts & pipeline
VIVOSIM LABS INC · Data as of 2026-09-08